Skip to main content
Erschienen in: Endocrine 3/2020

30.05.2020 | Research Letter

Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis

verfasst von: Mei Qiu, Shu-Yan Liu, Jin-Song Gu, Kai-Kai Li, Ling-Lin Li, Liang-Liang Ding

Erschienen in: Endocrine | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Excerpt

Large cardiovascular (CV) outcome trials demonstrated sodium glucose cotransporter 2 inhibitors (SGLT2is) could significantly reduce cardiorenal events in type 2 diabetic adults. However, the effects of SGLT2is on cardiorenal endpoints in many diabetic subpopulations are undefined because of the following two main reasons. …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat S.D. Wiviott, I. Raz, M.P. Bonaca et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380(4), 347–357 (2019)CrossRef S.D. Wiviott, I. Raz, M.P. Bonaca et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380(4), 347–357 (2019)CrossRef
2.
Zurück zum Zitat B. Neal, V. Perkovic, K.W. Mahaffey et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377(7), 644–657 (2017)CrossRef B. Neal, V. Perkovic, K.W. Mahaffey et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377(7), 644–657 (2017)CrossRef
3.
Zurück zum Zitat B. Zinman, C. Wanner, J.M. Lachin et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373(22), 2117–2128 (2015)CrossRef B. Zinman, C. Wanner, J.M. Lachin et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373(22), 2117–2128 (2015)CrossRef
4.
Zurück zum Zitat V. Perkovic, M.J. Jardine, B. Neal et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380(24), 2295–2306 (2019)CrossRef V. Perkovic, M.J. Jardine, B. Neal et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380(24), 2295–2306 (2019)CrossRef
5.
Zurück zum Zitat D. Fitchett, B. Zinman, C. Wanner et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the empa-reg outcome(r) trial. Eur. Heart J. 37(19), 1526–1534 (2016)CrossRef D. Fitchett, B. Zinman, C. Wanner et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the empa-reg outcome(r) trial. Eur. Heart J. 37(19), 1526–1534 (2016)CrossRef
6.
Zurück zum Zitat C. Wanner, S.E. Inzucchi, J.M. Lachin et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375(4), 323–334 (2016)CrossRef C. Wanner, S.E. Inzucchi, J.M. Lachin et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375(4), 323–334 (2016)CrossRef
7.
Zurück zum Zitat K. Radholm, G. Figtree, V. Perkovic et al. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation 138(5), 458–468 (2018)CrossRef K. Radholm, G. Figtree, V. Perkovic et al. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation 138(5), 458–468 (2018)CrossRef
8.
Zurück zum Zitat V. Perkovic, D. de Zeeuw, K.W. Mahaffey et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the canvas program randomised clinical trials. Lancet Diabetes Endocrinol. 6(9), 691–704 (2018)CrossRef V. Perkovic, D. de Zeeuw, K.W. Mahaffey et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the canvas program randomised clinical trials. Lancet Diabetes Endocrinol. 6(9), 691–704 (2018)CrossRef
9.
Zurück zum Zitat O. Mosenzon, S.D. Wiviott, A. Cahn et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the declare-timi 58 randomised trial. Lancet Diabetes Endocrinol. 7(8), 606–617 (2019)CrossRef O. Mosenzon, S.D. Wiviott, A. Cahn et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the declare-timi 58 randomised trial. Lancet Diabetes Endocrinol. 7(8), 606–617 (2019)CrossRef
10.
Zurück zum Zitat K.W. Mahaffey, M.J. Jardine, S. Bompoint et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation 140(9), 739–750 (2019)CrossRef K.W. Mahaffey, M.J. Jardine, S. Bompoint et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation 140(9), 739–750 (2019)CrossRef
11.
Zurück zum Zitat C.P. Cannon, V. Perkovic, R. Agarwal et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline hba1c, including those with hba1c <7%: results from the credence trial. Circulation 141(5), 407–410 (2020)CrossRef C.P. Cannon, V. Perkovic, R. Agarwal et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline hba1c, including those with hba1c <7%: results from the credence trial. Circulation 141(5), 407–410 (2020)CrossRef
12.
Zurück zum Zitat J. McMurray, S.D. Solomon, S.E. Inzucchi et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381(21), 1995–2008 (2019)CrossRef J. McMurray, S.D. Solomon, S.E. Inzucchi et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381(21), 1995–2008 (2019)CrossRef
13.
Zurück zum Zitat T.A. Zelniker, S.D. Wiviott, I. Raz et al. Sglt2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166), 31–39 (2019)CrossRef T.A. Zelniker, S.D. Wiviott, I. Raz et al. Sglt2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166), 31–39 (2019)CrossRef
14.
Zurück zum Zitat B.L. Neuen, T. Young, H. Heerspink et al. Sglt2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol, 7(11), 845–854 (2019)CrossRef B.L. Neuen, T. Young, H. Heerspink et al. Sglt2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol, 7(11), 845–854 (2019)CrossRef
15.
Zurück zum Zitat C. Arnott, Q. Li, A. Kang et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J. Am. Heart Assoc. 9(3), e14908 (2020)CrossRef C. Arnott, Q. Li, A. Kang et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J. Am. Heart Assoc. 9(3), e14908 (2020)CrossRef
16.
Zurück zum Zitat T. Toyama, B.L. Neuen, M. Jun et al. Effect of sglt2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes. Obes. Metab. 21(5), 1237–1250 (2019)CrossRef T. Toyama, B.L. Neuen, M. Jun et al. Effect of sglt2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes. Obes. Metab. 21(5), 1237–1250 (2019)CrossRef
17.
Zurück zum Zitat S.E. Inzucchi, D. Fitchett, D. Jurišić-Eržen et al. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy? Diabetes Obes. Metab. 22(4), 631–639 (2020)CrossRef S.E. Inzucchi, D. Fitchett, D. Jurišić-Eržen et al. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy? Diabetes Obes. Metab. 22(4), 631–639 (2020)CrossRef
18.
Zurück zum Zitat T. Ohkuma, L. Van Gaal, W. Shaw et al. Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the canvas program. Diabetes Obes. Metab. 22(4), 530–539 (2020)CrossRef T. Ohkuma, L. Van Gaal, W. Shaw et al. Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the canvas program. Diabetes Obes. Metab. 22(4), 530–539 (2020)CrossRef
19.
Zurück zum Zitat J.B. Buse, D.J. Wexler, A. Tsapas et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ada) and the european association for the study of diabetes (easd). Diabetes Care 43(2), 487–493 (2020)CrossRef J.B. Buse, D.J. Wexler, A. Tsapas et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ada) and the european association for the study of diabetes (easd). Diabetes Care 43(2), 487–493 (2020)CrossRef
Metadaten
Titel
Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis
verfasst von
Mei Qiu
Shu-Yan Liu
Jin-Song Gu
Kai-Kai Li
Ling-Lin Li
Liang-Liang Ding
Publikationsdatum
30.05.2020
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2020
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02359-5

Weitere Artikel der Ausgabe 3/2020

Endocrine 3/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.